Management Strategies in Antithrombotic Therapy
Management Strategies in Antithrombotic Therapy

By

ARMAN T. ASKARI
Cleveland Clinic Foundation, Cleveland, Ohio, USA

ADRIAN W. MESSERLI
St. Joseph’s Hospital, Lexington, Kentucky, USA

A. MICHAEL LINCOFF
Cleveland Clinic Foundation, Cleveland, Ohio, USA

John Wiley & Sons, Ltd
Management strategies in antithrombotic therapy / by Arman Askari and Michael Lincoff. p. ; cm.
Includes bibliographical references and index.
ISBN 978-0-470-31938-3 (alk. paper)
II. Messerli, Adrian W. III. Title.
[DNLM: 1. Coronary Thrombosis—drug therapy. 2. Heart Diseases—drug therapy. 3. Fibrinolytic 
Agents—therapeutic use. WG 300 A834m 2007]
RC694.3.A77 2007
616.1’42—dc22
2007024176

British Library Cataloguing in Publication Data
A catalogue record for this book is available from the British Library
Typeset in 10/12pt Times by Integra Software Services Pvt. Ltd, Pondicherry, India
Printed and bound in Great Britain by Antony Rowe Ltd, Chippenham, Wiltshire
This book is printed on acid-free paper responsibly manufactured from sustainable forestry
in which at least two trees are planted for each one used for paper production.
To my wife Jamie, and my children, Alexa, Amanda, and Jacob and to my parents Ali and Houri for their unwavering support.

Arman T. Askari, M.D.

To Marco...for coming.

Adrian W. Messerli, M.D.

To my wife, Debra, and my children, Gabrielle, Aaron, and Jacob - for their support and understanding.

A. Michael Lincoff, M.D.
Contents

Abbreviations and Acronyms xi

Preface xv

Chapter 1 Thrombosis and Antithrombotics in Vascular Disease 1
1.1 The Burden of Thrombosis 1
1.2 Essential components of thrombosis 1
1.3 Thrombosis in the acute ischemic syndromes 5
1.4 Venous thromboembolic disease 6
1.5 The ideal antithrombotic agent 10

Chapter 2 Aspirin 13
2.1 Introduction 13
2.2 Pharmacology 13
2.3 Clinical uses of aspirin 15
2.4 Conclusions 31

Chapter 3 Thienopyridines – Ticlopidine and Clopidogrel 37
3.1 Introduction 37
3.2 Pharmacology 37
3.3 Clinical uses of the thienopyridines 41
3.4 Conclusions 67

Chapter 4 Platelet Glycoprotein IIb/IIIa Inhibitors 77
4.1 Introduction 77
4.2 GP IIb/IIIa receptor inhibitors 78
4.3 GP IIb/IIIa inhibitors during percutaneous coronary revascularization 80
4.4 GP IIb/IIIa inhibitors in the management of non-st-elevation ACS 87
4.5 GP IIb/IIIa inhibitors in the management of acute STEMI 91
4.6 Safety of GP IIb/IIIa inhibitors 94
4.7 Summary 96

Chapter 5 Unfractionated Heparin 103
5.1 Introduction 103
5.2 Pharmacology 104
5.3 Clinical uses of UH 107
5.4 Clinical considerations 118
5.5 Conclusions 120
Chapter 6  Low-Molecular-Weight Heparins 129
  6.1 Introduction 129
  6.2 Comparisons between UH and LMWH 129
  6.3 Clinical uses of LMWH 133
  6.4 Conclusions 152

Chapter 7  Direct Thrombin Inhibitors 161
  7.1 Introduction 161
  7.2 Overview of DTIs 163
  7.3 Clinical uses of DTIs 166
  7.4 Summary 176

Chapter 8  Fibrinolytic agents 181
  8.1 Introduction 181
  8.2 Fibrinolytic agents for STEMI 181
  8.3 Fibrinolytics for VTE 195
  8.4 Conclusions 198

Chapter 9  Acute ST-Segment-Elevation Myocardial Infarction 205
  9.1 Introduction 205
  9.2 Definitive therapy 206
  9.3 Adjunctive therapy 213
  9.4 Recommendations 221
  9.5 Conclusions 225

Chapter 10  Acute Coronary Syndromes: Unstable Angina / Non-ST-Segment-Elevation Myocardial Infarction (NSTEMI) 233
  10.1 Introduction 233
  10.2 Antithrombotic approach to patients with ACS/NSTEMI 234
  10.3 Early invasive versus early conservative strategies 250
  10.4 Recommendations 252
  10.5 Conclusions 254

Chapter 11  Anticoagulation Strategies for Patients Undergoing Percutaneous Coronary Intervention 259
  11.1 Introduction 259
  11.2 Antiplatelet therapy 259
  11.3 Antithrombotic therapy 266
  11.4 Special populations 270
  11.5 Recommendations 273
  11.6 Conclusions 275

Chapter 12  Venous Thromboembolic Disease 283
  12.1 Introduction 283
  12.2 Risk of VTE 283
  12.3 Prevention of VTE 286
## CONTENTS

12.4 Treatment of VTE 294
12.5 Conclusions 303

Chapter 13  **Heparin-Induced Thrombocytopenia** 317
13.1 Introduction 317
13.2 Incidence 317
13.3 Pathogenesis 321
13.4 Clinical manifestations 324
13.5 Diagnosis 328
13.6 Prevention 330
13.7 Treatment 330
13.8 Conclusions 335

Index 343
Abbreviations and Acronyms

ABBREVIATIONS

AA               arachidonic acid
ACC              American College of Cardiology
ACE              angiotensin-converting enzyme
ACS              acute coronary syndrome(s)
ACT              activated clotting time
ADP              adenosine diphosphate
AHA              American Heart Association
AIVR             accelerated idioventricular rhythm
APSAC           antistreplase
aPTT            activated partial thromboplastin time
ASA              acetylsalicylic acid
AT               antithrombin
AUC              area under the curve
CABG            coronary artery bypass graft
CKD              chronic kidney disease
COX-1           cyclooxygenase-1
CRP              C-reactive protein
CV               cardiovascular
CVD              cardiovascular disease
CYP              cytochrome P450
DES              drug-eluting stents
DTI              direct thrombin inhibitors
DVT              deep vein thrombosis
EC               endothelial cell
ELISA           enzyme-linked immunosorbent assay
fVIIa/TF         serine protease factor VIIa
FDA              [US] Food and Drug Administration
GI               gastro-intestinal
HACA            human anti-chimeric antibody
HAT             heparin-associated thrombocytopenia
HCII            heparin cofactor II
HF              heart failure
HIPA           heparin-induced platelet aggregation
HIT            heparin-induced thrombocytopenia
HITTS         HIT with thrombosis syndrome
HMG CoA        hydroxymethylglutaryl-coenzyme A
HUVEC         human umbilical vein EC
ICAM         intracellular adhesion molecule
ICH  intracranial hemorrhage
IHD  ischemic heart disease
IL-1  interleukin-1
IL-8  interleukin-8
INR  international normalized ratio
IRA  infarct-related artery
IV  intravenous
IVIG  intravenous gamma globulin
LMWH  low-molecular-weight heparin
LTA  light transmittance platelet aggregation
LV  left ventricular
MI  myocardial infarction
NAP-2  neutrophil-activating-peptide-2
NPH  neutral protein Hagedorn
NSAID  non-steroidal anti-inflammatory drug
NSTE ACS  UA or NSTEMI
NSTEMI  non-ST-segment-elevation myocardial infarction
OPCAB  off-pump coronary artery bypass
PAD  peripheral arterial disease
PAI-1  plasminogen activator inhibitor-1
PAR  protease-activated receptor
PCI  percutaneous coronary intervention
PE  pulmonary embolism
PECAM-1  platelet–endothelial cell adhesion molecule 1
PF  platelet factor
PRP  platelet-rich plasma
PVD  peripheral vascular disease
RCT  randomized controlled trial
rNAPc2  recombinant nematode anticoagulant protein c2
r-PA  reteplase
rt-PA  recombinant tissue plasminogen activator
RR  relative risk
SAT  subacute thrombosis
SC  subcutaneous
SK  streptokinase
SRA  serotonin release assay
STEMI  ST-segment-elevation myocardial infarction
TEG  thrombelastography
TFPI  tissue factor pathway inhibitor
TIA  transient ischemia attack
TIMI  Thrombolysis in Myocardial Infarction
TNF  tumor necrosis factor
TNK  tenecteplase
t-PA  tissue plasminogen activator (alteplase)
TTP  thrombotic thrombocytopenic purpura
UA  unstable angina
UH  unfractionated heparin
UK urokinase
VCAM vascular adhesion molecule
VKA vitamin K antagonist
VTE venous thromboembolism
vWF von Willebrand factor

TRIAL/STUDY ACRONYMS

In the text trials and studies are referred to by their acronyms, which are collected here for convenience.

ACUITY A Randomized Trial of Angiomax versus Clexane in Patients Undergoing Early Invasive Management in Acute Coronary Syndromes without ST Elevation
ADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-term Follow-up
ALBION Assessment of the best Loading dose of clopidogrel to Blunt platelet activation, Inflammation and Ongoing Necrosis
ARMYDA-2 Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty
AT-BAT Anticoagulant Therapy with Bivalirudin to Assist in PCI
BAT Bivalirudin Angioplasty Trial
CADILLAC Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications
CAPRIE Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events
CAPTURE c7E3 Fab Anti-Platelet Therapy in Unstable Refractory Angina
CATS Canadian American Ticlopidine Study
CLARITY Clopidogrel as Adjunctive Reperfusion TherapY trial
CLASSICS Clopidogrel Aspirin Stent International Cooperative Study
COMMIT Clopidogrel Metoprolol Myocardial Infarction trial
CREDO Clopidogrel for the Reduction of Events During Observation
CURE Clopidogrel in Unstable Angina to Prevent Recurrent Events
EPIC Evaluation of c7E3 for Prevention of Ischemic Complications
EPILOG Evaluation in PTCA to Improve Long-term Outcome with Abciximab GP IIb/IIIa Blockade
EPISTENT Evaluation of Platelet Inhibition in Stenting
ESPRIT Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integritilin Therapy
ESSENCE Efficacy and Safety of Subcutaneous Enoxaparin in Unstable Angina and Non-Q-wave Myocardial Infarction
FANTASTIC Full ANTicoagulation versus ASpirin and TIClopidine
GRACE Global Registry of Acute Coronary Events
ISAR-REACT Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment
ISAR-CHOICE Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect